theresium
DR. KLOEPPEL
ZENTRUM FÜR ÄSTHETISCHE CHIRURGIE & MEDIZIN

Clinical Studies – Mariya Yankova MD

Several monocentric and multicentric observative studies in aesthetic dermatology (botulinum toxin, dermal filler, native hyaluronic acid, dermocosmetics, etc.) and surgery

1. Investigator Belove Merz 2025 – 04.2026
2. Investigator Décor Merz 2025 –ongoing
3. Co-investigator Platysma Merz 01.09.2025 -ongoing
4. Co-investigator in “A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Study of the Safety and Effectiveness of HAC 22L for improving Midface Volume“ (Aug 2023 – ongoing)
5. Co-investigator in "A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Group Study of the Safety and Effectiveness of HAC 20L for the Correction of Moderate to Severe Nasolabial Folds (The Visualize Study)" (Oct 2023 – June 2024)
6. Co-investigator in “Open-label, Multi-center, Randomized, Parallel-group, Post Market Clinical Follow-Up Investigation to Evaluate the Clinical Performance and Safety of Belotero® Volume and Belotero® Volume Lidocaine for Chin Augmentation” M940031001 (Sept 2022-July 2024)
7. Co-investigator in “A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines“ (Nov 2022-2023)
8. Co investigator in “A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence “ M21-310 EudraCT: 2021-000240-22 (May 2022-2023)
9. Co-investigator in “A Prospective, Multi-center Randomized, Controlled, Single-Blind Study of the Safety and Effectiveness of Algeness® DF 3.5% Deep Volumizing Filler in the Treatment of Age-Related Volume Deficit in the Mid-Face” AG35MF001 (March 2022-November 2024)
10. Co-investigator in “A randomized, multicenter, evaluator-blinded, active-controlled, parallel-group investigation to evaluate the performance and safety of YVOIRE® classic plus Versus Comparator for temporary correction of nasolabial folds” LG-HACL033 (January 2022-April 2023)

11. Co-investigator in "A prospective, multicenter, randomized, comparative, evaluator-blind study to evaluate the safety and effectiveness of Belotero® Volume Lidocaine for volume augmentation of the cheek" M930061001 (2021-June 2023)

12. Blinder investigator in "A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines" M602011071 (ULTRA I study) (2021 – May 2022)

13. Co investigator in "A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Study to Evaluate the Performance and Safety of YVOIRE Y-Solution 360 Versus Comparator for Temporary Enhancement and Pouting of the Lips for Lip Augmentation and Correction of Perioral Area" Study Number/LG-HACL023 EudraCT number: Eudamed: CIV-19-07-029264 (2020 – March 2021)

14. Blinder investigator in "Prospective, multicenter, parallel-group, evaluator-blind, randomized study to investigate the effectiveness and safety of MRZF111 in the treatment of décolleté wrinkles" M930521001 (2020 – April 2021)

15. Co investigator in "Open-label, multicenter, uncontrolled, randomized, post-market clinical follow-up (PMCF) study to confirm effectiveness and safety of Belotero® Revive in facial skin revitalization and photo-damaged skin treatment" M930001002 Belove-2.0
EudraCT number: NCT 03650387 (2019 – 2020)

16. Blinder investigator in "Open-label, multicenter, uncontrolled, rater-blinded, post-market clinical follow-up [PMCF] study to confirm performance and safety of RADIESSE® (+) Lidocaine in the treatment of nasolabial folds, marionette lines, and/or cheek volume loss" M900391005/RaLido (2018 – 2020)

17. Blinder investigator in "Open-label, multicenter, uncontrolled, rater-blinded, post-market clinical follow-up (PMCF) study to confirm performance and safety of Belotero® Soft Lidocaine and Belotero® Intense Lidocaine in the treatment of nasolabial folds, perioral fine lines and/or for lip volume enhancement" M900721001 / BISoLi (2018 – 2020)

18. Blinder investigator in "Open label multicenter post-market clinical follow-up study to confirm the safety of Belotero® Volume Lidocain in temporal hollows and cheeks" M930001001 (2016-2018)

19. Blinder investigator in “A prospective, open-label, multicenter, repeat-dose study to investigate the safety and efficacy of NT 201 (incobotulinumtoxinA) in the combined treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines), MRZ60201_3100_1 Eudra CT: 2014-003770-16 (2015 – 2016)

20. Blinder investigator in “A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of btx-a-hac ng in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of btx-a-hac ng following repeated treatments in this indication” 2014-003841-86; Y-52 52120-214 (2015 – 2016)